argenx vs Incyte
Incyte reported revenue of $5.1 billion in fiscal 2025, 1.2 times argenx's $4.2 billion in fiscal 2025. argenx's revenue grew 88.6% in its latest year, and Incyte's grew 21.2%. argenx had an operating margin of 24.8%, against 29.5% at Incyte. Free cash flow was $679 million at argenx and $1.4 billion at Incyte.
Side by side
| argenx | Incyte | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4.2B | $5.1B |
| Revenue growth | 88.6% | 21.2% |
| Revenue growth a year, last 5 years | 152.7% | 14.0% |
| Gross margin | 89.4% | 92.8% |
| Operating margin | 24.8% | 29.5% |
| Net margin | 30.4% | 25.0% |
| Free cash flow | $679M | $1.4B |
| Free cash flow margin | 16.0% | 26.4% |
| Return on capital | — | 79.4% |
| Net debt to EBITDA | — | −2.2x |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 1.3% | −4.7% |
| Last close | $942.04 | $115.87 |
| P/E at the last close | — | 61.6× |
| Insider trades, last 12 months | — | sold $67.8 million |
| Piotroski F-score | — | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
argenxIncyte
Operating margin
Percent of revenue
argenxIncyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
argenxIncyte